1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow Vepugratinib: new trials by email Literature Review of Vepugratinib trials Research Report on Vepugratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 Vepugratinib, Pembrolizumab, enfortumab vedotin - Urinary Bladder Neoplasms, Neoplasm Metastasis | Phase 1 | Recruiting | Eli Lilly and Company | 677 | 2023-01-12 | 2026-11-04 |
Neoplasm Metastasis (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Ureteral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urologic Neoplasms (1)
Australia (1) · Canada (1) · China (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)